JB Therapeutics Garners $662,000 New Financing Round

  • Feed Type
  • Date
    4/12/2012
  • Company Name
    JB Therapeutics
  • Mailing Address
    508 Dudley Road Newton Center, MA 02459
  • Company Description
    JB Therapeutics, Inc. is a clinical stage biopharmaceutical company developing the first new class of analgesic agents in two decades. Our lead compound, JBT-101, is a potent CB1 and CB2 agonist with demonstrated efficacy in several animal models of pain and inflammation. It has also completed a Phase II clinical study in chronic refractory neuropathic pain. JBT-101 is currently being developed as a potential disease modifying treatment for osteoarthritis.
  • Website
    http://www.jbtherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $662,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The company plans to use the money to run a Phase 2 clinical trial in the orphan disease systemic sclerosis, a type of scleroderma that affects the skin and vital internal organs such as the lungs, heart, and kidney.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy